• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Explaining the RE-LY Trial
【24h】

Explaining the RE-LY Trial

机译：解释RE-LY试用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In questioning the reliability of the RE-LY trial results, Tsang and others unfortunately based their concerns on a misinterpretation of the data that were published in the original trial report.The RE-LY trial, which had a study population of 18 000 patients, compared 2 doses of dabigatran etexilate with warfarin in the largest randomized controlled trial of antithrombotic therapy for stroke prevention ever performed. The results showed that, relative to warfarin, dabigatran 110 mg twice daily was associated with a similar rate of stroke and a lower rate of life-threatening, intracranial, major, minor, and total bleeding, whereas dabigatran 150 mg twice daily reduced stroke as well as life-threatening intracranial and total bleeding.
机译：在质疑RE-LY试验结果的可靠性时，Tsang和其他人不幸的是，他们对原始试验报告中公布的数据有误解。RE-LY试验的研究对象为18000名患者，在有史以来最大的抗血栓预防性卒中随机对照试验中，比较了2剂量达比加群酯与华法林的比较。结果表明，相对于华法林，每日两次110 mg的达比加群与中风发生率相似，并且威胁生命，颅内，大，轻度和总出血的发生率较低，而达比加群150 mg每天两次与中风相比降低卒中发生率。以及威胁生命的颅内出血和全部出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号